CoChat
Sign Up
Cited by 62

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Amyloid-β42 alters apolipoprotein E solubility in brains of mice with five familial AD mutations

Youmans, Katherine Lynn, Leung, Steffi, Zhang, Juan, Maus, Erika, Baysac, Kathleen, Bu, Guojun, Vassar, Robert, Yu, Chunjiang, LaDu, Mary Jo·2011·Journal of Neuroscience Methods
DOI 10.1016/j.jneumeth.2010.12.025PMC PMC3049315
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jneumeth.2010.12.025

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The sequential protein extraction method was optimized to extract lipoprotein-associated apoE to the TBSX fraction using 1% Triton X-100, allowing intact lipoproteins to extract in this fraction.

    “The protocol for this sequential protein extraction method was originally optimized to extract lipoprotein-associated apoE to the TBSX fraction by using 1%Triton X-100, a non-ionic detergent that is less stringent compared to SDS or Tween 20, allowing the intact lipoproteins to extract in this fraction [99].”

    From Inhibition of ACAT as a Therapeutic Target for Alzheimer's Disease Is Independent of ApoE4 Lipidation (2023) · cites this paper as [99]

    Methods §2.3 describes the TBSX extraction using 1% Triton X-100, and the Discussion says this method extracts lipoprotein-associated apoE primarily into TBSX in wild-type mice. The paper does not say that lipoprotein particles remain intact in that fraction or establish the claimed comparison with SDS or Tween 20. No page numbers are available in our copy. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

  • In the TBS-X fraction, APP/PS1; APOE4 control mice had lower apoE levels than APP/PS1; APOE3 control mice.

    “In the TBS-X fraction, which would be predicted to mainly contain membrane-associated proteins (22), APP/PS1; APOE4 control mice had lower APOE levels than APP/ PS1; APOE3 control mice.”

    From APOE4-mediated amyloid-β pathology depends on its neuronal receptor LRP1 (2019) · cites this paper as [22]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 38

  1. Aoki, 2008, Amyloid beta-peptide levels in laser capture microdissected cornu ammonis 1 pyramidal neurons of Alzheimer's brain, Neuroreport, 19, 1085, 10.1097/WNR.0b013e328302c858 · DOI · Paper page
  2. Brecht, 2004, Neuron-specific apolipoprotein E4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice, J Neurosci, 24, 2527, 10.1523/JNEUROSCI.4315-03.2004 · DOI · Paper page
  3. Burgess, 2008, ABCG1 influences brain cholesterol synthesis but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivo, J Lipid Res, 49, 1254, 10.1194/jlr.M700481-JLR200 · DOI
  4. Bush, 1990, The amyloid precursor protein of Alzheimer's disease is released by human platelets, J Biol Chem, 265, 15977, 10.1016/S0021-9258(18)55493-4 · DOI
  5. Caselli, 2010, Amyloid load in nondemented brains correlates with APOE E4, Neurosci Lett, 473, 168, 10.1016/j.neulet.2010.02.016 · DOI
  6. Cataldo, 2004, Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome, Neurobiol Aging, 25, 1263, 10.1016/j.neurobiolaging.2004.02.027 · DOI · Paper page
  7. Christensen, 2010, Accumulation of intraneuronal Abeta correlates with ApoE4 genotype, Acta Neuropathol, 119, 555, 10.1007/s00401-010-0666-1 · DOI · Paper page
  8. Cizas, 2010, Size-dependent neurotoxicity of beta-amyloid oligomers, Arch Biochem Biophys, 496, 84, 10.1016/j.abb.2010.02.001 · DOI
  9. Counts, 2006, Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment, J Neuropathol Exp Neurol, 65, 592, 10.1097/00005072-200606000-00007 · DOI
  10. David, 1997, The paired t test under artificial pairing, Am Statist, 51, 9
  11. Delacourte, 2002, Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease, Neurology, 59, 398, 10.1212/WNL.59.3.398 · DOI
  12. Di Luca, 1998, Differential level of platelet amyloid beta precursor protein isoforms: an early marker for Alzheimer disease, Arch Neurol, 55, 1195, 10.1001/archneur.55.9.1195 · DOI
  13. Elliott, 2009, Isoform-specific proteolysis of apolipoprotein-E in the brain, Neurobiol Aging, 32, 257, 10.1016/j.neurobiolaging.2009.02.006 · DOI
  14. Han, 1994, Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls, Exp Neurol, 128, 13, 10.1006/exnr.1994.1108 · DOI
  15. Hashimoto, 2002, CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXV, EMBO J, 21, 1524, 10.1093/emboj/21.7.1524 · DOI
  16. Kawarabayashi, 2004, Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease, J Neurosci, 24, 3801, 10.1523/JNEUROSCI.5543-03.2004 · DOI · Paper page
  17. Klein, 2001, Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?, Trends Neurosci, 24, 219, 10.1016/S0166-2236(00)01749-5 · DOI · Paper page
  18. Koob, 2010, GFAP reactivity, apolipoprotein E redistribution and cholesterol reduction in human astrocytes treated with alpha-synuclein, Neurosci Lett, 469, 11, 10.1016/j.neulet.2009.11.034 · DOI
  19. Lippel, 1983, Workshop on apolipoprotein quantification, Arteriosclerosis, 3, 452, 10.1161/01.ATV.3.5.452 · DOI
  20. Liu, 2007, Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1, Neuron, 56, 66, 10.1016/j.neuron.2007.08.008 · DOI · Paper page
  21. Love, 2006, Premorbid effects of APOE on synaptic proteins in human temporal neocortex, Neurobiol Aging, 27, 797, 10.1016/j.neurobiolaging.2005.04.008 · DOI
  22. Manelli, 2007, Abeta42 neurotoxicity in primary co-cultures: effect of apoE isoform and Abeta conformation, Neurobiol Aging, 28, 1139, 10.1016/j.neurobiolaging.2006.05.024 · DOI · Paper page
  23. Mastrangelo, 2008, Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice, BMC Neurosci, 9, 81, 10.1186/1471-2202-9-81 · DOI
  24. Naidu, 2001, Conversion of brain apolipoprotein E to an insoluble form in a mouse model of Alzheimer disease, Neuroreport, 12, 1265, 10.1097/00001756-200105080-00042 · DOI
  25. Oddo, 2003, Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction, Neuron, 39, 409, 10.1016/S0896-6273(03)00434-3 · DOI · Paper page
  26. Ohno, 2006, Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1, Eur J Neurosci, 23, 251, 10.1111/j.1460-9568.2005.04551.x · DOI · Paper page
  27. Patton, 2006, Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis, Am J Pathol, 169, 1048, 10.2353/ajpath.2006.060269 · DOI
  28. Potempska, 1991, Purification and tissue level of the beta-amyloid peptide precursor of rat brain, J Biol Chem, 266, 8464, 10.1016/S0021-9258(18)92997-2 · DOI
  29. Sullivan, 2009, Reduced levels of human apoE4 protein in an animal model of cognitive impairment, Neurobiol Aging
  30. Sullivan, 2004, Marked regional differences of brain human apolipoprotein E expression in targeted replacement mice, Neuroscience, 124, 725, 10.1016/j.neuroscience.2003.10.011 · DOI · Paper page
  31. Thal, 2008, Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease, J Cell Mol Med, 12, 1848, 10.1111/j.1582-4934.2008.00411.x · DOI · Paper page
  32. Van Nostrand, 1991, The predominant form of the amyloid beta-protein precursor in human brain is protease nexin 2, Proc Natl Acad Sci USA, 88, 10302, 10.1073/pnas.88.22.10302 · DOI
  33. Wahrle, 2007, Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms, Mol Neurodegener, 2, 7, 10.1186/1750-1326-2-7 · DOI · Paper page
  34. Weidemann, 1989, Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein, Cell, 57, 115, 10.1016/0092-8674(89)90177-3 · DOI
  35. Youmans KL. The effects of human apoE on amyloid-beta (42) pathology and synaptic loss in a novel transgenic mouse model. American Society for Neurochemistry. Transactions of the American Society for Neurochemistry: Santa Fe, NM; 2010.
  36. Yu, 2010, Endocytic pathways mediating oligomeric Abeta42 neurotoxicity, Mol Neurodegener, 5, 19, 10.1186/1750-1326-5-19 · DOI
  37. Yu, 2010, Proposed mechanism for lipoprotein remodelling in the brain, Biochim Biophys Acta, 1801, 819, 10.1016/j.bbalip.2010.05.001 · DOI
  38. Zhao, 2007, Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis, J Neurosci, 27, 3639, 10.1523/JNEUROSCI.4396-06.2007 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Youmans, K. L., Leung, S., Zhang, J., Maus, E., Baysac, K., Bu, G., Vassar, R., Yu, C., & LaDu, M. J.
Venue
Journal of Neuroscience Methods
Publisher
Elsevier BV
Published
2011-03
Volume
196
Issue
1
Pages
51-59
ISSN
0165-0270
DOI
10.1016/j.jneumeth.2010.12.025
PMC
PMC3049315
Cited by
62
References
19
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review